艾司西酞普兰联合层级护理模式治疗伴焦虑的抑郁障碍患者研究

目的:探讨艾司西酞普兰联合层级护理模式治疗伴焦虑的抑郁障碍患者的临床疗效。方法:将84例伴焦虑的抑郁障碍患者随机分为干预组(42例)和对照组(42例),干预组采用艾司西酞普兰联合层级护理模式治疗,对照组给予艾司西酞普兰合并常规护理治疗,治疗6周。治疗前、治疗后1、2及6周进行汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)以及世界卫生组织生存量表(WHOQL-BREF)评分,比较两组患者的临床疗效。结果:治疗6周末,干预组总有效率为90.48%,对照组为85.71%,两组间差异无统计学意义(P>0.05)。干预组HAMD-17评分和HAMA评分治疗后2周分别为(12.65±3.41)和(12.67±8.13)均低于对照组[分别为(17.40±4.40)和(16.50±4.40)],差异均有统计学意义(P均<0.05)。干预组和对照组治疗前后WHOQL-BREF评分分别为(54.35±6.63)和(56.85±6.81)分,差异无统计学意义(P>0.05)。结论:艾司西酞普兰联合层级护理模式治疗伴焦虑的抑郁障碍起效更快。

Study on escitalopram combined with hierarchical nursing model among anxiety associated depressive patients

Objective:To explore the clinical efficacy of escitalopram combined with hierarchical nursing model in the treatment of anxiety associated depression disorder.Method:84 patients with anxiety associated depression were randomly divided into intervention group(n=42)and control group(n=42).The intervention group was treated with escitalopram combined with hierarchical nursing mode,and the control group was treated with escitalopram combined with conventional nursing.Both groups were treated for 6 weeks.Hamilton Depression Scale(HAMD-17),Hamilton Anxiety Scale(HAMA)and World Health Organization survival scale(WHOQL-BREF)and the clinical efficacy of the two groups were compared at baseline and 1,2 and 6 weeks after treatment.Results:At the end of 6 weeks,the total effective rate of intervention group was 90.48%,and that of control group was 85.71%,there was no significant difference between the two groups(P>0.05).The HAMD-17 score and HAMA score of intervention group were(12.65±3.41)and(12.67±8.13)at 2 weeks after treatment,which were lower than those in the control group[(17.40±4.40)and(16.50±4.40),respectively].The difference was statistically significant(P<0.05).The WHOQL-BREF scores of intervention group and control group at baseline and after treatment were(54.35±6.63)and(56.85±6.81),respectively,with no significant difference(P>0.05).Conclusion:Escitalopram combined with hierarchical nursing model has earlier response in patients with anxiety associated depression disorder.